Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

AGM Update

19 Jun 2013 13:16

RNS Number : 4011H
PuriCore Plc
19 June 2013
Β 

ο»Ώ

19 June 2013

PuriCore plc

Β ("PuriCore" or the "Company")

Β 

Modification to the Value Creation Plan Proposed as Resolution 10 for Approval at the PuriCore Annual General Meeting

Β 

PuriCore (LSE: PURI) today announces that the Board has modified the terms of the Value Creation Plan proposed as Resolution 10 to be approved at the Company's Annual General Meeting, following further consultation with shareholders.

Β 

The first change is to limit the number of ordinary shares that can be awarded under the Value Creation Plan and any other outstanding employee share schemes to 10% of the outstanding share capital of the Company. Secondly, the base price will be set at the average share price over the 30 days following the announcement of the Company's half yearly results, which are expected in early August 2013.

Β 

Details of the proposed Value Creation Plan are available in a letter from the chairman of the Remuneration Committee on PuriCore's investor website at investor.puricore.com in the Annual General Meeting section. The 2013 Annual General meeting will be held 26 June 2013.

Β 

Enquiries:

Β 

UK

US

FTI Consulting

Sage Strategic Marketing

Susan Stuart

Jennifer Guinan

Victoria Foster Mitchell

+1 610.410.8111

+44 (0) 20 7831 3113

jennifer@sagestrat.com

Β 

Β 

About PuriCore

PuriCore plc (LSE: PURI) is a global company focused on developing and commercialising proprietary solutions that protect people from the spread of infectious pathogens without causing harm to human health or the environment. PuriCore's antimicrobial technology and complementary products are used principally in well-established core businesses and emerging sectors of two broad markets: Health Sciences and Food & Agriculture. In the Health Sciences market, PuriCore is the leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients in UK hospitals. PuriCore's breakthrough wound therapy solution is used to treat chronic and acute wounds including diabetic ulcers and burns as well as atopic dermatitis as dermatologic treatment products. In the Food & Agriculture market, both Sterilox Fresh and FloraFresh provide savings to supermarket retailers in labour costs and improvements in inventory loss of fresh produce and floral products. In addition, the Company is progressing in its research and development programmes at Oxford University on the use of its technology as an agricultural fungicide. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, visit www.puricore.com.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCNKCDDBBKDPAD
Date   Source Headline
11th Jun 20072:32 pmRNSPresenting at Conference
11th Jun 200712:18 pmRNSHolding(s) in Company
31st May 200710:14 amRNSResult of AGM
23rd May 200712:00 pmBUSFDA Lists Sterilox Food Safety Solution for Food Contact
23rd May 20077:02 amRNSRe: Food Safety Solution
21st May 200712:00 pmBUSStudy Shows PuriCore's Aquatine(TM) EC Effective for Root Canal Disinfecting and Cleansing
14th May 20075:57 pmRNSAnnual Information Update
25th Apr 20079:14 amRNSDirector/PDMR Shareholding
19th Apr 200710:45 amRNSHolding(s) in Company
19th Apr 20079:54 amRNSDirector/PDMR Shareholding
18th Apr 20074:00 pmRNSHolding(s) in Company
18th Apr 20077:01 amRNSDirector/PDMR Shareholding
16th Apr 20077:02 amRNSFinal Results
5th Apr 200712:00 pmBUSPuriCore Receives FDA 510(k) Approval for Endoscope Disinfectant System in US
5th Apr 20077:01 amRNSFDA 510(k) Approval
29th Mar 20078:00 amRNSNotice of Results
27th Mar 20071:54 pmBUSPuriCore signs additional endoscope reprocessor marketing partnership
27th Mar 20071:02 pmRNSSigns Marketing Partnership
5th Mar 20075:12 pmRNSHolding(s) in Company
5th Feb 20077:01 amRNSRe Agreement
5th Feb 20077:01 amRNSTrading Update
26th Jan 20073:44 pmRNSRe: Section 198
8th Jan 20077:00 amRNSFundraising
18th Dec 20064:01 pmRNSTransparency Rule
8th Dec 20062:00 pmRNSGreg Bosch Wins CEO of Year
13th Nov 20067:02 amRNSAppointment
7th Nov 20063:47 pmRNSRe Interest in Shares
7th Nov 20063:44 pmRNSInterest in Shares
13th Sep 20067:03 amRNSAppointments
13th Sep 20067:03 amRNSContract
13th Sep 20067:03 amRNSInterim Results
21st Aug 200611:05 amRNSHolding(s) in Company
16th Aug 200611:12 amRNSNotice of Results
7th Aug 20063:43 pmRNSBlocklisting Applications

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.